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Abstract 
Background: It has been shown that use of rapid diagnostic tests (RDTs) is able to reduce costs and improve the prescribing practice 
of antivirals (i.e. oseltamivir) among patients with influenza-like illnesses (ILIs). Using existing Clinical Laboratory Improvement 
Amendment (CLIA)-waived RDTs and collaborative practice agreements, similar to those used to allow pharmacists to administer 
vaccines, it is possible for patients to seek point-of-care treatment for influenza or flu-like symptoms at a local pharmacy. Following a 
review of the patient’s symptoms by a trained pharmacist, the qualified patient is offered an RDT to determine if the influenza virus is 
the cause of the symptoms. Based on the results of the RDT, the patient is provided with the appropriate treatment as defined by an 
approved practice agreement.  Objective: The aim of this study was to evaluate the feasibility of incorporating an RDT for influenza 
into community pharmacy practice. Methods: This time and motion study was conducted at three community pharmacy locations, 
and a total of eight simulated patient visits were completed utilizing a standardized patient. In addition to determining a total time of 
the encounter, each simulation was divided into nine timed sub-categories.  For data analysis, the time spent in each of the nine sub-
categories was assigned to the pharmacist, pharmacy technician, or patient. Time and motion methodologies were used to estimate 
the total time required to provide the RDT service, to determine the amount of active time required of the pharmacist and pharmacy 
technician, and to evaluate the ability of the staff to provide the service within its existing workflow.  Results: The average total time 
to complete the entire patient encounter for an influenza assessment utilizing an RDT was 35.5 minutes (± 3.1 minutes). On average, 
the pharmacist spent 9.4 minutes (± 3 minutes) per encounter or about 26.5% of the entire encounter. When the pharmacy 
technician collected the vital signs, the pharmacist-required time was reduced to 4.95 minutes (± 2.7 minutes), which was about a 
48% reduction.  Conclusions: The results indicate that an RDT program for influenza assessment required no more than a modest 
amount of pharmacist time and could be successfully incorporated into regular workflow with little to no disruption of other 
activities. As such, this approach to influenza management may be a feasible service for community pharmacies to offer patients. 
This was especially true if the pharmacy had well-trained technicians on staff that could support the service with collection of patient 
histories and vital signs.  
 
 
Introduction 
With ongoing implementation of the Affordable Care Act, the 
traditional delivery models of health care are bound to 
change.  As highly accessible health care professionals, 
community pharmacists could be looked to as an alternative 
avenue in which patients can receive efficient and quality 
care for acute illnesses.  One such illness for which 
pharmacists could make a significant impact is influenza. Each 
year 6 to20% of United States residents are infected with 
influenza.  While influenza is a self-limiting illness requiring 
little or no treatment for many patients, more than 200,000  
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people are hospitalized due to influenza and influenza-related 
complications each year.1 It is important to treat individuals 
diagnosed with influenza with the proper antiviral therapy. If 
started within 48 hours of the onset of symptoms, the 
antivirals may decrease the severity of symptoms, shorten 
the duration of a patient’s sickness by 1 to 2 days, decrease 
the risk of viral transmission, and prevent serious flu-related 
complications.2 This study aims to evaluate the feasibility of 
incorporating a rapid diagnostic test (RDT) for influenza into 
community pharmacy practice. 
 
It has been shown that RDTs are able to reduce costs and 
improve the prescribing practice of antivirals (i.e. oseltamivir) 
in patients with influenza-like illnesses (ILIs).3 Using existing 
Clinical Laboratory Improvement Amendments (CLIA) waived 
rapid diagnostic tests and collaborative practice agreements 
similar to those used by pharmacists determining the need 
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for and administering vaccines, it is possible to provide 
patients with point-of-care treatment for influenza or flu-like 
symptoms at a local pharmacy. Upon arrival at the pharmacy 
and following a review of history and symptoms with the 
pharmacist, the patient undergoes a brief physical 
assessment and is offered the RDT to determine if the patient 
is infected with the influenza virus.  Based on the results of 
the RDT and physical assessment findings, the patient is 
managed according to an approved protocol.  Patients who 
are deemed to be at high risk for complications and/or exhibit 
signs of clinical instability (i.e. patients with hypotension, 
hyperventilation, low oxygenations, etc.) are referred to a 
physician for management. 
 
In order for the use of RDTs for influenza to be a feasible 
service within a community pharmacy three criteria must be 
met.  First, it needs to contribute to provision of high quality 
patient-centered care.  Secondly, it must be offered at a 
competitive cost.  Lastly, it must not be unduly disruptive to 
the existing pharmacy workflow or consume an excessive 
amount of pharmacist time.  As part of a larger community 
pharmacy-based RDT study, we conducted a time and motion 
analysis to determine whether or not an RDT program could 
be practically offered in a community pharmacy. The purpose 
of this study was to estimate the time costs associated with 
provision of an influenza disease management program in a 
community pharmacy.  Specifically, we sought to determine 
the amount of active time required of the pharmacist and 
pharmacy technician(s), and to evaluate the ability of the 
pharmacy staff to provide the service within its existing 
workflow.   
 
Key Findings 
 
• The average total time it took to complete the entire 
patient encounter for a rapid diagnostic influenza 
test was 35.5 minutes (± 3.1 minutes). 
• The average pharmacist participation time per 
encounter was 9.4 minutes (± 3 minutes). 
• When a pharmacy technician collects patient vital 
signs, the pharmacist participation time per 
encounter was 4.95 minutes (± 2.7 minutes). 
• The results of this study indicate that the 
incorporation of a RDT for the influenza virus into an 
influenza disease management program could be a 
feasible service offered in a community pharmacy. 
 
Study Methods 
This time and motion study was conducted at three 
community pharmacy locations participating in a larger rapid 
diagnostic testing study. A single standardized patient was 
used to portray a patient with ILI presenting to the 
participating sites. Patient visits were observed by a 
researcher trained in time and motion study methodologies. 
This study did employ the direct observation and timing 
techniques used in a traditional time and motion study, but 
the nature of the observed service, with the lack of clearly 
defined steps, makes it something of a hybrid between a time 
and motion and work sampling study.  The study was 
approved by the Institutional Review Board of the University 
of Nebraska Medical Center. 
The methodologies for conducting this study were as follows:  
Each simulated encounter was divided into nine timed 
categories.  The time of the entire encounter was also 
documented.  Timed categories included: 
 
1. Patient arrival at the counter until presence noted by 
pharmacy staff 
2. Initial patient contact with pharmacy staff and 
screening 
3. Patient completion of paperwork/review of 
symptoms 
4. Pharmacist consultation 
5. Waiting for RDT/physical assessment 
6. Collection of vital signs 
7. Performance of RDT 
8. Waiting for test results 
9. Patient counseled on treatment plan   
The first category encompassed the time from the patient’s 
arrival at the community pharmacy counter until a member 
of the pharmacy staff acknowledged the patient’s presence.  
Once the patient’s presence was noted the second category 
began.  This category included the discussion between the 
technician and patient about what brought the patient into 
the pharmacy that day.  When the patient described 
symptoms matching the symptoms listed in the influenza 
management protocol, the technician provided the patient 
with the paperwork necessary for the initial assessment.  As 
the patient filled out the paperwork, the third category began 
and included the time it tool for the technician to confirm the 
answers provided with the patient.  In addition, the third 
category included the time it took for the pharmacist to 
assess the paperwork.   
 
The fourth category, the first with active participation by the 
pharmacist, began when the pharmacist approached the 
counter to review the symptoms with the patient and to 
advise the patient to receive an RDT.  This fourth category 
ended by the beginning of the patient’s wait for the 
RDT/physical assessment to be performed (category 5).  The 
wait period was time the patient spends in the waiting area 
of the pharmacy or the time the patient spent in the 
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consultation room waiting for the pharmacy staff to set up 
the supplies necessary to take vital signs and perform the 
RDT.  It may have also been the time when the payment for 
the rapid diagnostic test is transacted. 
The sixth category started when the pharmacy staff began 
collection of the patient’s vital signs.  The order in which vital 
signs were collected and the individual times associated with 
each were not recorded.  Rather, the total time it took to 
record the patient’s temperature, blood pressure, pulse, 
respiratory rate, and oxygen saturation was recorded as a 
single number for the sixth category.   
Select pharmacy technicians were trained to use automated 
blood pressure devices, pulse oximeters, and temporal scan 
thermometers. This left each study site with the freedom to 
decide whether the vital signs were to be assessed by the 
pharmacist or a technician trained in an accredited program. 
 
The start of the seventh category was signaled by the 
collection of specimen for processing. This category included 
the process of performing the nasal swab and processing the 
sample according to manufacturer’s instructions.  In this 
study, the Sofia Influenza A+B Fluorescent Immunoassay (FIA) 
(Quidel Corporation, San Diego, CA) was the RDT used.  All 
tests were performed in accordance with the package insert 
for the Sofia system being used in the “walk away mode”.4 
Specific steps included the preparation of the reagent, nasal 
swab specimen collection, insertion of the swab into the 
reagent tube, and filling of the sample cassette. 
 
The eighth category was defined as the time that the patient 
spent waiting for the RDT results.  The Sofia system used in 
this study takes approximately 15 minutes to provide results.  
During this time the pharmacist was able to resume other 
pharmacy tasks.  At the end of the 15 minutes, the 
pharmacist returned to the consultation room to discuss the 
results of the test with patient.  Based on the results the 
pharmacist counseled the patient on the management plan 
(category 9). 
 
While the categories above are described to follow a step-by-
step timeline, modifications to this timeline can be made.  For 
instance, category 6 (collection of vital signs) can be 
conducted during category 8 (patient waiting for the test 
results).  By doing this, not only will the pharmacist or 
technician be able to take more accurate measurements of 
the patient’s vital signs because they will have been seated 
for a longer time, but the total time spent by the patient in 
the pharmacy will potentially be reduced.   
 
This study did not include the time necessary to dispense a 
prescription (if appropriate) or purchase an over the counter 
product, since that would be part of the existing pharmacy 
workflow.  It would be no different than the pharmacy filling 
a prescription brought in by a patient who had been 
diagnosed by their physician. 
 
For data analysis, the time spent in each of the nine 
categories was assigned to the pharmacist, technician, or the 
patient (labeled as “waiting time”).  Depending on whether or 
not the pharmacist collected the vital signs, this sub-category 
was assigned to the respective member of the pharmacy 
team.  The different groupings used to allocate time 
measurements to the pharmacist, technician, and patient can 
be seen in Table 1. 
 
 
Table 1: Groupings of Pharmacist, Technician, and Patient Time 
Point of Care Sequence 1:  
Technician does not perform vitals 
Point of Care Sequence 2:  
Technician performs vitals 
Patient time in either 
sequence 
 Pharmacist Time Tech Time Pharmacist Time Tech time Total “waiting time” 
for patient 
(4) Pharmacist 
consult  
 
(6) Collection of 
Vital Signs 
 
(7) Rapid 
Diagnostic Test  
 
(9)Patient 
counseled on 
treatment  
(2) Initial patient 
contact with 
pharmacy staff 
 
(3) Pt. Completion 
of paperwork/ 
review of 
symptoms  
(4) Pharmacist 
consult  
 
(7) Rapid 
Diagnostic Test  
 
(9) Patient 
counseled on 
treatment 
(2) Initial patient 
contact with 
pharmacy staff  
 
(3) Pt. Completion 
of paperwork/ 
review of 
symptoms  
 
(6) Collection of 
Vital signs  
(1) Patient arrival at 
the counter until 
presence noted by 
pharmacy staff  
 
(5) Waiting for rapid 
diagnostic test/ 
physical assessment  
 
(8) Waiting for test 
results  
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Results 
A total of eight simulated patient visits were completed by 
the standardized patient at the three locations.  Visits took 
place over two days in June 2013, were made between 9 AM 
and 5 PM, and were made without knowledge of or regard 
for staffing or workload levels.  The timed results from the 
three pharmacies in the time and motion study can be seen in 
Table 2a-c (time measured in seconds).   
 
Table 2a: Three Timed Encounters at Pharmacy 1 
Pharmacy 1 Encounter 11 Encounter 21,2 Encounter 31,2 
Patient Arrives at Counter 31 19 27 
Patients’ Presence Noted 86 259 248 
Patient completion of paperwork/ review of symptoms 200 233 358 
Pharmacist Consult/ 140 58 34 
Waiting for rapid diagnostic  test/ physical assessment 371 414 444 
Rapid Diagnostic Test 155 136 149 
Vital Signs 0 390 385 
Waiting for Test Results 1024 606 615 
Patient Counseled on Treatment 54 32 32 
Total Time 2061 2147 2292 
1All times were recorded in seconds 
2For encounters 2 and 3, the vital signs were collected while the patient waited for the results of the RDT. 
 
Table 2b: Two Timed Encounters at Pharmacy 2 
Pharmacy 2 Encounter 11 Encounter 21 
Patient Arrives at Counter 10 19 
Patients’ Presence Noted 20 135 
Patient completion of paperwork/ review of symptoms 125 65 
Pharmacist Consult 30 31 
Waiting for rapid diagnostic test/ physical assessment 192 276 
Rapid Diagnostic Test 92 189 
Vital Signs 449 176 
Waiting for Test Results 1005 954 
Patient Counseled on Treatment 5 5 
Total Time 1928 1850 
 1All times were recorded in seconds 
 
Table 2c: Three Timed Encounters at Pharmacy 3 
Pharmacy 3 Encounter 11,2 Encounter 21,2 Encounter 31,2 
Patient Arrives at Counter 27 56 19.2 
Patients’ Presence Noted 181 54 100 
Patient completion of paperwork/ review of symptoms 354 217 100 
Pharmacist Consult 20 83 24 
Waiting for rapid diagnostic test/physical assessment 397 530 600 
Rapid Diagnostic Test 137 417 462 
Vital Signs 266 367 180 
Waiting for Test Results 667 538 921 
Patient Counseled on Treatment 10 50 30 
Total Time 2059 2312 2436.2 
1All times were recorded in seconds 
2For all encounters, the vital signs were collected while the patient waited for the results of the RDT. 
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As the results of the eight visits indicate, the average total 
time it took to complete the entire patient encounter was 
35.5 minutes (± 3.1 minutes). Of that time, the average time 
it took for the pharmacist to complete the initial 
consultation/review of symptoms, RDT, the collection of vital 
signs, and the counseling of the patient on an appropriate 
treatment plan was 9.4 minutes (± 3 minutes). Encounters in 
which the pharmacist collected vital signs will be referred to 
as option 1.  In this option, pharmacists were involved in 
26.5% of the entire encounter.  The two most time-
consuming steps for the pharmacist were the performing the 
RDT and the collection of vital signs.  If a pharmacy technician 
collected the vital signs (option 2), the average time the 
pharmacist spends per encounter was reduced to 4.95 
minutes (± 2.7 minutes).  This resulted in about a 48% 
reduction in the pharmacist time requirement.  For the 
patient, the average total wait time spent at the pharmacy 
was 20.6 minutes.  The majority of the patient’s time was 
spent waiting for the RDT results.  As mentioned, the testing 
time for the Sofia analyzer system is minimally 15 minutes.  
 
In most cases, a patient’s encounter time could be reduced if 
the vital signs (whether collected by the pharmacist or the 
technician) were collected during the time the RDT is 
processing.  This was evident in the second and third 
encounters at Pharmacy 1, as well as the three encounters at 
Pharmacy 3.  In all five of these encounters, the wait time for 
the results was shorter than the wait time the patient spent 
at Pharmacy 2 (where the vital signs are done before the 
RDT).   
 
Table 3. Time required based on staff member assessing vital signs 
 Min Max Average 
Total Encounter Time 30.8 40.6 35.5 
Point of Care Option 1. Pharmacist Time w/ Vitals 5.82 15.28 9.4 
Point of Care Option 1. Tech Time w/o Vitals 2.25 10.1 5.56 
Point of Care Option 2. Pharmacist Time w/o Vitals 2.12 9.17 4.95 
Point of Care Option 2. Tech Time w/ Vitals 4.77 16.52 10.05 
Total Patient “Waiting Time” 17.3 25.7 20.6 
*Time recorded in minutes 
 
The numerical values in Table 3 are presented again in a graphical manner below: 
 
 
Figure 1: Average time required to conduct service 
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Figure 2a: Summary of Average Time Requirements in Point of Care Option 1 
 
 
 
Figure 2b: Summary of Average Time Requirements in Point of Care Option 2 
 
*Category 6 is the collection of vital signs.  In option 1, vital sign collection was done by the pharmacist.  In option 2, vital 
sign collection was done by the pharmacy technician 
** Categories 1-9 correlate to the nine categories utilized in this time and motion study. [(1) Patient arrival at the counter 
until presence noted by pharmacy staff, (2) Initial patient contact with pharmacy staff and screening, (3)Patient completion 
of paperwork/review of symptoms, (4) Pharmacist consultation, (5) Waiting for RDT/physical assessment, (6) Collection of 
vital signs, (7) Performance of RDT, (8) Waiting for test results, (9) Patient counseled on treatment plan] 
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Discussion 
When analyzing the data collected, it is important to 
recognize the limitations of this study.  A primary limitation of 
was the presence of the observer. While the observer did not 
interact directly with the pharmacy staff, they were aware of 
his presence.  This awareness may have increased the anxiety 
of the staff and thus affected the speed at which they 
performed activities.   
The second limitation relates to the timing associated with 
the third category (patient completion of paperwork/review 
of symptoms).  From the description above, it is evident this 
category required some pharmacist time for paperwork 
evaluation, but it was minimal compared to the time the 
patient spent talking with the technician and filling out 
paperwork.  Even though the third category included 
numerous steps within the pharmacy’s RDT workflow, the 
entire time spent in this category was grouped under 
technician time in the results portion of this study.  This was 
due to the fact that, in this real-life pharmacy setting, the 
observer was unable to see all the individual steps occurring 
behind the counter.  Since this category did not always have 
clearly-defined times assigned to the pharmacist, technician, 
and patient, it is recognized as a limitation of the study.  
 
The third limitation deals with when the pharmacy staff was 
trained and when the study was actually conducted.  The 
pharmacy staff was originally trained on the skills required to 
conduct an RDT and vital signs in December 2012.  While the 
staff had the opportunity to conduct the service during the 
2012-2103 influenza season, roughly three months had 
passed between the last actual patient presenting and the 
first standardized patient simulation in June 2013.  Moreover, 
due to late implementation of the RDT program, some staff 
members had not tested a patient during the influenza 
season, so the simulated patient was their first “real” 
experience in providing the service.  As such, the pharmacies 
were probably not at peak efficiency for the time and motion 
study.  With each simulation, however, the staff’s confidence 
and efficiency in conducting the vital signs and RDT improved.  
While the relatively small number of observations is a 
limitation of this study, there was enough variation between 
sites and visits to suggest that we had achieved a fairly 
representative sample.   
 
Even with consideration of the limitations, the results of this 
analysis show that an RDT for influenza could be a feasible 
service for community pharmacies to offer patients.  In 
observing the pharmacies, it was noted that the pharmacy 
staff was able to work the rapid diagnostic testing into the 
regular workflow with little to no disruption of other 
activities.  This is especially true if the pharmacy had well-
trained technicians on staff.  By delegating the collection of 
vital signs to technicians, the pharmacist dedicated 
approximately 5 minutes per patient encounter, which 
primarily consisted of sample collection, test interpretation, 
and patient counseling.  
 
Some of the pharmacies in this study also identified the 
potential benefit of collecting the vital signs while waiting for 
the test results because, by doing so, the patient’s wait time 
could be reduced..  This may be appropriate and prove to be 
beneficial since the vital signs influence the treatment 
decision and not the testing decision.  It is also possible that 
the measurements of the patient’s vital signs will be more 
accurate since the patient will have been seated for a longer 
period of time. 
 
When considering the possibility of incorporating rapid 
diagnostic testing for influenza into a community pharmacy’s 
workflow, it may be useful to compare it to the time required 
to administer vaccines in the community pharmacy setting.  
According to one study, the average wait period and 
vaccination time for a patient receiving a flu shot is 
approximately 12 minutes.5 While the overall time required 
for the RDT is longer, the majority of that time does not 
require active involvement from the pharmacist or 
technician, making the two services comparable in terms of 
resources used.  It is also worth noting that the per-visit 
revenue for a rapid diagnostic testing service may be two to 
three times higher than an influenza vaccination visit.  
 
Implementation and delivery of an influenza rapid diagnostic 
testing service is still in its infancy.  Pharmacists and 
technicians are still learning how to best develop and deliver 
these services in their practice settings.  In follow-up 
discussions with the pharmacists and technicians, they 
admitted to being nervous about and somewhat 
uncomfortable with providing this novel service, but they also 
recognized how much easier and more confident they felt 
after providing the service one time.  Moreover, they felt 
that, with practice, they would be able to deliver this service 
within their existing workflow just as they do with 
vaccinations. 
 
Conclusion 
Though additional studies examining patient demand and 
willingness to pay for this type of service are needed before 
feasibility can be fully assessed, this study indicates that an 
influenza rapid diagnostic testing service could be 
incorporated into an existing community pharmacy with 
limited disruption to the workflow and staffing levels.   
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